Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1724 participants.
Also called NCT05836740
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,724 participants
- Registry
-
NCT05836740
-
- Other papers using this trial's data
- Efficacy and safety of minocycline in patients with acute ischaemic stroke (EMPHASIS): a multicentre, double-blind, randomised controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05836740. Randomized; quadruple masking; primary purpose treatment. Start 2023-05-19 (actual); primary completion 2024-05-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke
- Acronym
- EMPHASIS
- Condition
- Ischemic Stroke, Acute
- Intervention (Drug)
- Minocycline hydrochloride capsule
- Intervention (Drug)
- Placebo capsules of Minocycline hydrochloride capsules
- Lead sponsor
- Beijing Tiantan Hospital
- Collaborator
- Neurodawn Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct05836740- Content hash
4bcb17a2b81dfb01cfce34abbe480e954046bc0dfe94f70d2c95ded5d6851350